Table 1 : Baseline characteristics of patients.


  PT group
(n=20)
Control group
(n=20)
P

Gender (M/F) 10/10 11/9 0.752
Age (years) 67.2±7.9 66.9±6.3 0.877
Height (cm) 159.3±10.2 158.7±7.9 0.769
Weight (kg) 55.0±13.4 56.1±10.3 0.668
Duration of disease (Y) 8.7±6.1 11.4±5.8 0.166
Hoehn & Yahr stage 3.3±0.5 3.4± 0.5 0.635

UPDRS score      

Total 39.4±17.1 38.4±13.0 0.882
Mental 1.4±1.7 1.8±1.4 0.221
ADL 11.1±6.0 12.5±7.4 0.529
Motor 25.1±10.7 21.1±7.8 0.414
Complications 1.9±2.0 3.0±3.7 0.512

Medication      

Levodopa use 16 (80%) 17(85%) 0.677
Dopa agonist use 12 (60%) 16(80%) 0.168
Other PD medication 15 (75%) 16(80%) 0.705
Mean dose of levodopa (mg/day) 318 (139) 350 (153) 0.486

Note: Values are given as mean(SD) unless otherwise indicated
ADL: Activities of daily living; PD: Parkinson's disease;
UPDRS: Unified Parkinson Disease Rating Scale

Wada et al.Physical Therapy and Rehabilitation  2014 1:5DOI : 10.7243/2055-2386-1-5